The BC Bud Co. Applauds DEA Action, Prepares for North American Opportunities and Provides Corporate Update

Rhea-AI Impact
Rhea-AI Sentiment

The BC Bud (CSE: BCBC) (OTCQB: BCBCF) applauds DEA action to reschedule cannabis, preparing for North American opportunities. The US Department of Justice may reclassify cannabis as a Schedule III controlled substance, aligning it with prescription medications. The company is exploring M&A opportunities, focusing on direct delivery initiatives, and anticipating a prosperous 2024 in the cannabis market.

BC Bud (CSE: BCBC) (OTCQB: BCBCF) esprime apprezzamento per l'azione della DEA di riclassificare la cannabis, preparandosi per opportunità in Nord America. Il Dipartimento di Giustizia degli Stati Uniti potrebbe riclassificare la cannabis come sostanza controllata di Tabella III, equiparandola ai farmaci su prescrizione. L'azienda sta esplorando opportunità di fusione e acquisizione, concentrando gli sforzi sulle iniziative di consegna diretta e prevedendo un prospero 2024 nel mercato della cannabis.
BC Bud (CSE: BCBC) (OTCQB: BCBCF) aplaude la acción de la DEA para reclasificar el cannabis, preparándose para oportunidades en América del Norte. El Departamento de Justicia de EE.UU. podría reclasificar el cannabis como una sustancia controlada del Anexo III, equiparándola con los medicamentos con receta. La compañía está explorando oportunidades de fusiones y adquisiciones, enfocándose en iniciativas de entrega directa y anticipando un próspero 2024 en el mercado del cannabis.
BC Bud (CSE: BCBC) (OTCQB: BCBCF)는 대마초의 일정 재조정을 위한 DEA의 조치를 환영하며 북미 시장의 기회를 준비하고 있습니다. 미국 법무부는 대마초를 처방약과 동일한 계획 III 통제 물질로 재분류할 수 있습니다. 회사는 M&A 기회를 모색하고 있으며 직접 배송 이니셔티브에 집중하고 있으며 2024년 대마초 시장에서 번영할 것으로 예상하고 있습니다.
BC Bud (CSE: BCBC) (OTCQB: BCBCF) salue l'action de la DEA pour reclasser le cannabis, se préparant pour les opportunités en Amérique du Nord. Le Département de la Justice des États-Unis pourrait reclasser le cannabis comme une substance contrôlée de l'Annexe III, le mettant au même niveau que les médicaments sur ordonnance. L'entreprise explore des opportunités de fusion et acquisition, se concentre sur les initiatives de livraison directe et anticipe une année 2024 prospère sur le marché du cannabis.
BC Bud (CSE: BCBC) (OTCQB: BCBCF) begrüßt die Maßnahme der DEA zur Neuklassifizierung von Cannabis und bereitet sich auf Chancen in Nordamerika vor. Das US-Justizministerium könnte Cannabis als kontrollierte Substanz des Anhangs III einstufen, was es mit verschreibungspflichtigen Medikamenten gleichsetzt. Das Unternehmen erkundet Möglichkeiten für Fusionen und Übernahmen, konzentriert sich auf Direktlieferinitiativen und erwartet ein erfolgreiches Jahr 2024 auf dem Cannabis-Markt.
  • The BC Bud Co. applauds the DEA action to reschedule cannabis, recognizing the medicinal benefits and potential growth opportunities in the industry.

  • The company's focus on responsibility, maturity, and longevity, supported by financial prudence and industry expertise, positions it well for sustainable growth.

  • The BC Bud Co. is actively pursuing M&A prospects in North America and beyond, leveraging its experience and seeking strategic partnerships for future growth.

  • The company's initiative on direct delivery services enhances accessibility and transparency of its premium cannabis products, strengthening customer-centric services.

  • As Canada's cannabis market matures and bottoms out, The BC Bud Co. is strategically positioned for a prosperous and transformative 2024, welcoming stakeholders to join in its journey.

  • None.

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - The BC Bud Corporation (CSE: BCBC) (OTCQB: BCBCF) ("The BC Bud Co" or the "Company"), a house of high-quality cannabis brands based out of British Columbia, Canada, applauds the DEA and US Federal movement towards rescheduling cannabis.

The Biden administration is poised to reclassify cannabis as a substance of lower risk, marking a historic and timely shift that recognizes the medicinal benefits of a long-criminalized and unfairly stigmatized drug. This move carries significant implications for cannabis-related research and the industry as a whole.

The US Department of Justice is anticipated to suggest the rescheduling of cannabis as a Schedule III controlled substance. This classification aligns it with prescription medications like ketamine and Tylenol with codeine.

"The BC Bud Co has long awaited this historic shift and remains dedicated to evaluating opportunities across North America and soon globally to introduce our brands to evolving consumer markets," stated CEO Brayden Sutton. "We are confident in our positioning for growth, despite the challenges present in the cannabis sector. Preparation for this change has involved ongoing discussions with key US contacts over an extended period. With conditions becoming increasingly favorable for commerce in the cannabis space, we are committed to advancing these discussions further."

Focused on Responsibility, Maturity and Longevity

The BC Bud Co. stands out as a responsible yet street-smart participant in the cannabis market. Backed by a history of financial prudence and deep-rooted experience in the industry, the company has primarily relied on funding from its founders and management, laying a robust foundation for sustainable growth with ready access to capital as needed. By consciously opting to remain asset-light, the company prioritizes its products and the consumer experience over infrastructure and human capital.

Exploring M&A Opportunities

Primed for strategic growth in North America and beyond, The BC Bud Co. is actively pursuing promising Merger and Acquisition prospects, though at this time no specific transactions have progressed beyond initial negotiations. Drawing upon its wealth of industry expertise, the company is ready to forge potential partnerships in the United States and abroad. Moreover, The BC Bud Co. is actively scouting for US-based advisors to access top-tier, value-enhancing opportunities.

Direct Delivery Initiatives

Aligned with its dedication to customer-centric services, The BC Bud Co. is ramping up its focus on direct delivery services to bolster the accessibility and transparency of its premium cannabis products with new BC-based partners.

Anticipating a Prosperous 2024

As Canada enters its sixth year of cannabis legalization, The BC Bud Co. looks ahead with optimism, particularly as the sector navigates a bottoming-out phase. Positioned strategically, the company is poised to seize emerging opportunities for a prosperous and transformative 2024. The BC Bud Co. welcomes stakeholders, partners, and the public to join in its journey toward ongoing success. For further details, please visit or reach out via email at

About The BC Bud Co.

The BC Bud Co. is a publicly traded Canadian cannabis company headquartered in British Columbia. Renowned for its responsibility, maturity, and unwavering commitment to quality, the company is steadfastly dedicated to overcoming the challenges inherent in the cannabis sector while striving for sustained growth.

Investor Relations
Phone: 1-(778)-656-0377


Forward-Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties, and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions, including the effects of COVID-19. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.

Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit

The BC Bud Corporation


BCBCF Rankings

BCBCF Latest News

BCBCF Stock Data

Investment Banking and Securities Dealing
Finance and Insurance
United States of America